Loading…
Vivanza Biosciences (BSE 530057)₹1.45−2.03%Pharmaceuticals
In the Jun 2026 quarter (consolidated), Vivanza Biosciences reported sales of ₹9.27 Cr, up 3.9% from Jun 2025, and net profit of ₹0.14 Cr, up 75.0% year on year. For the year to Mar 2026, sales were ₹116 Cr and net profit ₹0 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 7.60 | 6.55 | 4.41 | 2.43 | 2.99 | 1.49 | 0.47 | 8.92 | 55.25 | 45.15 | 6.35 | 9.27 |
| Expenses | 7.29 | 6.26 | 4.55 | 2.07 | 2.88 | 1.36 | 1.43 | 8.80 | 54.74 | 45.00 | 6.60 | 9.35 |
| Operating Profit | 0.33 | 0.28 | −0.13 | 0.37 | 0.12 | 0.12 | −0.95 | 0.16 | 0.60 | 0.20 | −0.24 | −0.06 |
| OPM % | 4.2% | 4.4% | −3.2% | 14.7% | 3.7% | 8.6% | −200.1% | 1.7% | 1.1% | 0.5% | −3.7% | −0.8% |
| Other Income | 0.06 | 0.03 | −0.04 | 0.00 | 0.00 | 0.02 | 0.06 | 0.03 | 0.02 | 0.09 | 0.02 | 0.38 |
| Interest | 0.10 | 0.09 | 0.08 | 0.08 | 0.08 | 0.08 | 0.07 | 0.07 | 0.04 | 0.08 | 0.06 | 0.10 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.00 |
| Profit before tax | 0.25 | 0.20 | −0.26 | 0.26 | 0.01 | 0.04 | −0.98 | 0.08 | 0.56 | 0.19 | −0.29 | 0.17 |
| Tax % | 0.0% | 0.0% | 55.6% | 0.0% | 0.0% | 0.0% | 1.0% | 0.0% | 0.0% | 0.0% | 50.1% | 22.3% |
| Net Profit | 0.25 | 0.22 | −0.42 | 0.26 | 0.01 | 0.03 | −0.99 | 0.08 | 0.57 | 0.19 | −0.46 | 0.14 |
| EPS (Rs) | 0.05 | 0.04 | −0.09 | 0.06 | 0.00 | 0.00 | −0.24 | 0.01 | 0.13 | 0.04 | −0.10 | 0.03 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.00 | 2.99 | 5.99 | 2.99 | 9.97 | 9.98 | 9.97 | 17.97 | 27.95 | 6.98 | 116 | 116 |
| Expenses | 0.00 | 3.99 | 6.01 | 3.01 | 9.99 | 9.99 | 9.99 | 16.99 | 26.98 | 7.99 | 115 | 116 |
| Operating Profit | 0.00 | 0.00 | 1.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.99 | 0.99 | 0.00 | 1.01 | 0.50 |
| OPM % | — | −9.1% | 8.9% | −0.8% | −3.6% | 0.9% | −0.6% | 3.8% | 3.9% | −4.9% | 0.6% | 0.4% |
| Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 1.01 | 1.01 | 1.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.51 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.28 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 |
| Profit before tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.99 | 0.99 | −0.99 | 0.99 | 0.63 |
| Tax % | 0.0% | 0.0% | 13.1% | 0.0% | 0.0% | 42.0% | 0.0% | 17.0% | 21.0% | 2.0% | 27.1% | — |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.01 | 1.01 | −0.99 | 0.00 | 0.44 |
| EPS (Rs) | −0.31 | −0.07 | 0.04 | −0.10 | −0.04 | 0.01 | 0.07 | 0.14 | 0.13 | −0.16 | 0.09 | 0.10 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.19 | 4.01 | 4.00 | 4.00 | 3.99 | 4.00 | 4.00 | 4.00 | 3.99 | 4.00 | 4.00 |
| Reserves | 0.00 | 0.00 | 0.00 | −1.00 | −1.01 | −1.00 | −1.01 | 0.00 | 1.01 | 0.00 | 0.00 |
| Borrowings | 0.00 | 1.00 | 1.00 | 1.00 | 0.00 | 0.00 | 6.00 | 8.00 | 4.99 | 9.01 | 10.00 |
| Other Liabilities | 0.01 | 3.01 | 5.02 | 6.02 | 9.05 | 5.02 | 7.04 | 10.05 | 10.05 | 4.02 | 8.04 |
| Total Liabilities | 1.01 | 7.02 | 10.02 | 11.02 | 12.03 | 8.02 | 16.03 | 22.05 | 20.04 | 16.03 | 22.04 |
| Fixed Assets | 0.00 | 2.01 | 2.01 | 2.01 | 2.01 | 2.01 | 2.01 | 2.01 | 2.01 | 2.01 | 2.01 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 1.01 | 5.01 | 8.01 | 9.01 | 10.02 | 6.01 | 13.02 | 20.04 | 17.03 | 14.02 | 20.03 |
| Inventories | 0.00 | 1.80 | 2.27 | 1.99 | 0.96 | 0.64 | 2.42 | 2.46 | 2.00 | 2.25 | 3.54 |
| Trade receivables | 0.00 | 2.52 | 5.06 | 5.69 | 6.53 | 6.24 | 7.82 | 12.45 | 11.51 | 8.04 | 12.36 |
| Cash & equivalents | 0.02 | −2.32 | −2.96 | −2.99 | −2.77 | −3.08 | 0.05 | 0.13 | 0.16 | 0.11 | 0.06 |
| Total Assets | 1.01 | 7.02 | 10.02 | 11.02 | 12.03 | 8.02 | 16.03 | 22.05 | 20.04 | 16.03 | 22.04 |
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | −1.99 | 0.00 | 1.01 | 3.01 | −2.99 | 1.99 | −0.99 | 2.01 | −1.99 | −3.01 |
| Cash from investing activity | 1.99 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from financing activity | 0.00 | −1.01 | −1.01 | −3.01 | 3.01 | −2.01 | 1.01 | −2.01 | 2.01 | 3.01 |
| Net cash flow | 0.00 | −0.99 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Capex | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.03 | 0.00 | 0.11 |
| Free cash flow | −2.01 | 0.00 | 1.01 | 3.01 | −3.01 | 2.01 | −1.01 | 2.01 | −3.01 | −3.01 |
| CFO / OP % | 668.0% | −15.0% | −4,300.0% | −876.0% | −3,367.0% | −4,117.0% | −124.0% | 203.0% | 692.0% | −328.0% |
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 267 | 287 | 782 | 250 | 231 | 275 | 256 | 151 | 398 | 39 |
| Inventory days | 215 | 150 | 309 | 38 | 26 | 92 | 55 | 28 | 121 | 11 |
| Days payable | 304 | 319 | 878 | 319 | 154 | 207 | 211 | 116 | 140 | 23 |
| Cash conversion cycle | 178 | 118 | 213 | −32 | 103 | 160 | 99 | 64 | 379 | 27 |
| Working capital days | 333 | 238 | 470 | 110 | 105 | 104 | 51 | 45 | 155 | 8 |
| ROCE % | −10.1% | 12.9% | 0.0% | 6.0% | 16.9% | 11.9% | 10.9% | 9.9% | −3.0% | 6.0% |
For the Jun 2026 quarter, Vivanza Biosciences reported sales of ₹9.27 Cr, up 3.9% year on year and net profit of ₹0.14 Cr, up 75.0% year on year. The operating margin was −0.8%.
Vivanza Biosciences' sales for the year to Mar 2026 were ₹116 Cr; over the last twelve months they were ₹116 Cr.
Net profit for the year to Mar 2026 was ₹0 Cr, and ₹0.44 Cr over the last twelve months. Earnings per share over the same trailing period were ₹0.10.
Vivanza Biosciences reported borrowings of ₹10 Cr at Mar 2026, against cash and equivalents of ₹0.06 Cr.
Cash from operations was −₹3.01 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹3.01 Cr.